155 related articles for article (PubMed ID: 34847357)
1. MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts.
Papadopoulos D; Solvie D; Baluapuri A; Endres T; Ha SA; Herold S; Kalb J; Giansanti C; Schülein-Völk C; Ade CP; Schneider C; Gaballa A; Vos S; Fischer U; Dobbelstein M; Wolf E; Eilers M
Mol Cell; 2022 Jan; 82(1):159-176.e12. PubMed ID: 34847357
[TBL] [Abstract][Full Text] [Related]
2. Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase.
Herold S; Kalb J; Büchel G; Ade CP; Baluapuri A; Xu J; Koster J; Solvie D; Carstensen A; Klotz C; Rodewald S; Schülein-Völk C; Dobbelstein M; Wolf E; Molenaar J; Versteeg R; Walz S; Eilers M
Nature; 2019 Mar; 567(7749):545-549. PubMed ID: 30894746
[TBL] [Abstract][Full Text] [Related]
3. Conflict resolution by MYCN.
Moorefield B
Nat Struct Mol Biol; 2022 Feb; 29(2):84. PubMed ID: 35149862
[No Abstract] [Full Text] [Related]
4. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
Haug BH; Hald ØH; Utnes P; Roth SA; Løkke C; Flægstad T; Einvik C
Anticancer Res; 2015 May; 35(5):2521-30. PubMed ID: 25964525
[TBL] [Abstract][Full Text] [Related]
5. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
6. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.
Mandriota SJ; Valentijn LJ; Lesne L; Betts DR; Marino D; Boudal-Khoshbeen M; London WB; Rougemont AL; Attiyeh EF; Maris JM; Hogarty MD; Koster J; Molenaar JJ; Versteeg R; Ansari M; Gumy-Pause F
Oncotarget; 2015 Jul; 6(21):18558-76. PubMed ID: 26053094
[TBL] [Abstract][Full Text] [Related]
7. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of Aurora-A and ATR kinase results in regression of
Roeschert I; Poon E; Henssen AG; Garcia HD; Gatti M; Giansanti C; Jamin Y; Ade CP; Gallant P; Schülein-Völk C; Beli P; Richards M; Rosenfeldt M; Altmeyer M; Anderson J; Eggert A; Dobbelstein M; Bayliss R; Chesler L; Büchel G; Eilers M
Nat Cancer; 2021 Mar; 2(3):312-326. PubMed ID: 33768209
[TBL] [Abstract][Full Text] [Related]
9. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
Di Giulio S; Colicchia V; Pastorino F; Pedretti F; Fabretti F; Nicolis di Robilant V; Ramponi V; Scafetta G; Moretti M; Licursi V; Belardinilli F; Peruzzi G; Infante P; Goffredo BM; Coppa A; Canettieri G; Bartolazzi A; Ponzoni M; Giannini G; Petroni M
Oncogene; 2021 Oct; 40(43):6143-6152. PubMed ID: 34508175
[TBL] [Abstract][Full Text] [Related]
10. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
11. An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.
Nagy Z; Seneviratne JA; Kanikevich M; Chang W; Mayoh C; Venkat P; Du Y; Jiang C; Salib A; Koach J; Carter DR; Mittra R; Liu T; Parker MW; Cheung BB; Marshall GM
Nat Commun; 2021 Mar; 12(1):1881. PubMed ID: 33767157
[TBL] [Abstract][Full Text] [Related]
12. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
13. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
15. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.
Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K
Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729
[TBL] [Abstract][Full Text] [Related]
16. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
17. Proteome dynamics at broken replication forks reveal a distinct ATM-directed repair response suppressing DNA double-strand break ubiquitination.
Nakamura K; Kustatscher G; Alabert C; Hödl M; Forne I; Völker-Albert M; Satpathy S; Beyer TE; Mailand N; Choudhary C; Imhof A; Rappsilber J; Groth A
Mol Cell; 2021 Mar; 81(5):1084-1099.e6. PubMed ID: 33450211
[TBL] [Abstract][Full Text] [Related]
18. The super elongation complex drives transcriptional addiction in
Wang D; Yin Z; Wang H; Wang L; Li T; Xiao R; Xie T; Han R; Dong R; Liu H; Liang K; Qing G
Sci Adv; 2023 Mar; 9(13):eadf0005. PubMed ID: 36989355
[No Abstract] [Full Text] [Related]
19. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
[TBL] [Abstract][Full Text] [Related]
20. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
